Consun Pharmaceutical Group (1681) H2 2025 earnings summary

Executive summary

• Revenue for 2025 reached RMB3.42 billion, up 15.2% year-over-year, with profit attributable to equity shareholders rising 18.4% to RMB1.08 billion.

• Gross profit margin improved to 78.0% from 75.6% due to production efficiency and supplier optimization.

• Core product lines, especially kidney medicines, drove growth, with kidney medicines sales up 20.3% and medical contrast medium up 10.9%.

• R&D and digitalization were emphasized, with new drug approvals and international clinical trials initiated.

• The company maintained a strong liquidity position and continued to invest in innovation and operational efficiency.

Financial highlights

• Revenue: RMB3,417,355,000 (+15.2% YoY); Gross profit: RMB2,667,120,000 (+19.0% YoY).

• Profit attributable to equity shareholders: RMB1,078,067,000 (+18.4% YoY).

• Basic EPS: RMB1.27 (+14.4% YoY); Diluted EPS: RMB1.26 (+15.6% YoY).

• Gross profit margin: 78.0% (+2.4pp YoY); Effective tax rate: 9.0% (down 1.1pp YoY).

• Final dividend proposed: HKD0.40 per share; total dividend for the year: HKD0.73 per share (>50% payout ratio).

Outlook and guidance

• Focus on high-quality growth through organizational reform, digital transformation, and scientific marketing.

• Continued investment in R&D, digitalization, and operational efficiency to drive sustainable growth.

• Anticipates further normalization of medical insurance cost control and targeted centralized procurement in 2026.